Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioFront Trial: MO-03 + SOC Immunotherapy in Advanced Clear Cell Renal Cell Carcinoma
NCT07383441Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Jun 2026
- Primary completion
- Jan 2033
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 3 trial of clostridium butyricum in clear cell renal cell carcinoma (ccRCC), sponsored by SWOG Cancer Research Network. Started Jun 2026; status: recruiting.
02
Drugs
clostridium butyricum
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07383441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07383441.